Absci Corporation successfully dosed the first three cohorts in the single ascending dose phase of its ABS-201 HEADLINE trial for androgenetic alopecia, reporting favorable safety data. The company revealed human ex vivo data showing ABS-201 stimulates hair growth by regenerating follicle stem cells. Absci also appointed Dr. Ransi Somaratne as Chief Medical Officer to lead clinical strategy. With cash to fund operations into mid-2028, Absci plans interim proof-of-concept data for ABS-201 in late 2026 and aims to start a Phase 2 trial for endometriosis by year-end, targeting significant unmet medical needs in both conditions.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
